Roundup cancer claims have exploded into a constitutional brawl in St. Louis, where lawyers for a group of plaintiffs are urging a Missouri judge to slam the brakes on Bayer’s proposed $7.25 billion class-action settlement. In objections filed last Thursday, the lawyers argue the deal strips current and future cancer victims of basic due-process protections. A day later, last Friday, the objectors escalated the fight by filing a notice of removal to federal court, a procedural move that could upend the timeline and the entire path to approval. The settlement blueprint carves out roughly $675 million for attorneys, sets a June 4 opt-out deadline and is slated for a July fairness hearing.
According to The New Lede, last Thursday's filings do not mince words, branding the deal a "sweetheart" arrangement that runs roughshod over basic due process rights. The objections take particular aim at a so-called "futures" subclass that, they say, could scoop up people who merely "saw" someone use Roundup. The objectors also contend that the opt-out process is so complex and burdensome that many injured people will be effectively locked into the program and steered away from individual trials.
Removal bid seeks federal review
An attorney for the objectors has asked the U.S. District Court for the Eastern District of Missouri to take over, filing a notice of removal last Friday and urging that the dispute be shipped to a California federal court where Judge Vince Chhabria has managed much of the consolidated Roundup litigation. Christopher Seeger, one of the lawyers behind the settlement deal, blasted the maneuver as "a baseless delay tactic that should be promptly denied," according to AP News.
What's in the deal
Bayer says the proposed program would provide declining, capped annual payments over as many as 21 years, with a total value of up to $7.25 billion to resolve current and future non-Hodgkin lymphoma claims, according to a Bayer news release. Critics counter that class counsel have asked for roughly $675 million in fees, while individual payouts could vary widely based on exposure levels and age, a concern detailed by The New Lede.
Timeline and high-stakes questions
The deal carries a June 4 opt-out deadline and a July 9 final fairness hearing. At the same time, the U.S. Supreme Court is expected to rule in the related Durnell case by the end of June, a decision that could weaken many state-court failure-to-warn claims and alter plaintiffs’ leverage, as reported by AP News. Objectors warn that the tight opt-out window, combined with those looming deadlines, could leave many class members stuck in the settlement and unable to pursue individual lawsuits if they later change their minds.
Why lawyers say the fight matters
The objectors argue that a fast-tracked state-court process, a sweeping futures subclass and strict opt-out rules would short-circuit jury trials and shift value away from victims and toward lawyers. Supporters of the settlement respond that it offers a guaranteed recovery in a moment when a Supreme Court win for Bayer could otherwise wipe out large numbers of claims. The removal gambit itself is legally novel, asking courts to treat objecting plaintiffs as if they were defendants for purposes of removal, and it could decide whether the fight plays out in Missouri, in California or on appeal.
